HALO vs. RKLB
HALO (Halozyme Therapeutics, Inc.) and RKLB (Rocket Lab USA, Inc.) are both stocks. HALO operates in Biotechnology (Healthcare), while RKLB operates in Aerospace & Defense (Industrials). Over the past 3 years, HALO returned 27.10%/yr vs 158.32%/yr for RKLB. At a 0.25 correlation, their price movements are largely independent.
Performance
HALO vs. RKLB - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, HALO achieves a 3.27% return, which is significantly lower than RKLB's 46.77% return.
HALO
- 1D
- -1.74%
- 1M
- 0.42%
- YTD
- 3.27%
- 6M
- 11.72%
- 1Y
- 28.75%
- 3Y*
- 27.10%
- 5Y*
- 10.19%
- 10Y*
- 22.84%
RKLB
- 1D
- -10.79%
- 1M
- -22.75%
- YTD
- 46.77%
- 6M
- 66.51%
- 1Y
- 302.95%
- 3Y*
- 158.32%
- 5Y*
- —
- 10Y*
- —
HALO vs. RKLB - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
HALO Halozyme Therapeutics, Inc. | 3.27% | 40.77% | 29.36% | -35.04% | 41.51% | -1.20% |
RKLB Rocket Lab USA, Inc. | 46.77% | 173.89% | 360.58% | 46.68% | -69.30% | 8.67% |
Correlation
The correlation between HALO and RKLB is 0.12, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.12 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.20 |
Correlation (All Time) Calculated using the full available price history since Aug 24, 2021 | 0.25 |
The correlation between HALO and RKLB shifts across timeframes, from 0.12 (1 year) to 0.25 (all time), reflecting how their relationship changes across market environments.
Fundamentals
HALO:
$8.54B
RKLB:
$61.99B
HALO:
$2.87
RKLB:
-$0.33
HALO:
5.61
RKLB:
83.69
HALO:
38.88
RKLB:
27.38
HALO:
$1.51B
RKLB:
$679.58M
HALO:
$1.23B
RKLB:
$248.43M
HALO:
$980.05M
RKLB:
-$177.36M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
HALO vs. RKLB — Risk / Return Rank
HALO
RKLB
HALO vs. RKLB - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Halozyme Therapeutics, Inc. (HALO) and Rocket Lab USA, Inc. (RKLB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| HALO | RKLB | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.21 | ||
| Sortino ratioReturn per unit of downside risk | -1.73 | ||
| Omega ratioGain probability vs. loss probability | 1.17 | 1.38 | -0.21 |
| Calmar ratioReturn relative to maximum drawdown | 1.14 | 6.74 | -5.60 |
| Martin ratioReturn relative to average drawdown | 2.16 | 15.44 | -13.27 |
Loading charts...
Drawdowns
HALO vs. RKLB - Drawdown Comparison
The maximum HALO drawdown since its inception was -74.26%, smaller than the maximum RKLB drawdown of -82.96%. Use the drawdown chart below to compare losses from any high point for HALO and RKLB.
Loading charts...
Drawdown Indicators
| HALO | RKLB | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -74.26% | -82.96% | +8.70% |
Max Drawdown (1Y)Largest decline over 1 year | -24.13% | -43.01% | +18.88% |
Max Drawdown (3Y)Largest decline over 3 years | -33.92% | -55.49% | +21.57% |
Max Drawdown (5Y)Largest decline over 5 years | -49.06% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -49.06% | — | — |
Current DrawdownCurrent decline from peak | -14.44% | -31.84% | +17.40% |
Average DrawdownAverage peak-to-trough decline | -31.88% | -51.29% | +19.41% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 12.73% | 18.75% | -6.02% |
Volatility
HALO vs. RKLB - Volatility Comparison
The current volatility for Halozyme Therapeutics, Inc. (HALO) is 8.94%, while Rocket Lab USA, Inc. (RKLB) has a volatility of 31.54%. This indicates that HALO experiences smaller price fluctuations and is considered to be less risky than RKLB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| HALO | RKLB | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 8.94% | 31.54% | -22.60% |
Volatility (6M)Calculated over the trailing 6-month period | 24.02% | 73.47% | -49.45% |
Volatility (1Y)Calculated over the trailing 1-year period | 30.20% | 93.03% | -62.83% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 39.42% | 81.62% | -42.20% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 42.88% | 81.62% | -38.74% |
Dividends
HALO vs. RKLB - Dividend Comparison
Neither HALO nor RKLB has paid dividends to shareholders.
Financials
HALO vs. RKLB - Financials Comparison
This section allows you to compare key financial metrics between Halozyme Therapeutics, Inc. and Rocket Lab USA, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
HALO vs. RKLB - Profitability Comparison
HALO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Halozyme Therapeutics, Inc. reported a gross profit of 297.47M and revenue of 376.71M. Therefore, the gross margin over that period was 79.0%.
RKLB - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Rocket Lab USA, Inc. reported a gross profit of 76.49M and revenue of 200.35M. Therefore, the gross margin over that period was 38.2%.
HALO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Halozyme Therapeutics, Inc. reported an operating income of 184.52M and revenue of 376.71M, resulting in an operating margin of 49.0%.
RKLB - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Rocket Lab USA, Inc. reported an operating income of -55.97M and revenue of 200.35M, resulting in an operating margin of -27.9%.
HALO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Halozyme Therapeutics, Inc. reported a net income of 150.05M and revenue of 376.71M, resulting in a net margin of 39.8%.
RKLB - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Rocket Lab USA, Inc. reported a net income of -45.02M and revenue of 200.35M, resulting in a net margin of -22.5%.
Frequently Asked Questions
HALO and RKLB have a correlation of 0.12, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
RKLB has higher volatility (31.54%) compared to HALO (8.94%). In terms of maximum drawdown, HALO dropped -74.26% vs RKLB's -82.96%.
RKLB currently has the higher Sharpe Ratio (3.12 vs 0.91), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for HALO and RKLB
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer